Woodford Woes Drag On For Immunocore
Unrealistic Valuations Holding Private Firms Back
Executive Summary
Once seen as the champion of biotech start-ups, Woodford’s blind faith has shackled firms to unrealistic valuations.
You may also be interested in...
Troubled Immunocore Reawakens With New $130m Funding
After a record breaking Series A fundraising, the UK biotech hit a series of problems. Can a new CEO and new funding help it fulfil its promise?
Autolus Faces Life After Woodford With New Czech Backer
PPF has bought a big stake in the UK-based T-cell specialist, one of many firms backed by investor Neil Woodford which have suffered stock slides in the past few months.
Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.